Novo Nordisk A/S shares climbed by 1.52% today to 888.60 DKK, following the release of promising new data on its obesity drug Liraglutide, which has been shown to be safe and effective in children as young as six. The Danish pharmaceutical giant has experienced significant stock growth in recent years, driven by surging demand for […]
Novo Nordisk’s diabetes medication, Victoza (liraglutide), has gained U.S. Food and Drug Administration (FDA) approval for an expanded use, marking a significant step forward in the treatment of cardiovascular diseases among type 2 diabetes patients. This latest approval allows Victoza to be used to reduce the risk of major adverse cardiovascular events (MACE), including cardiovascular […]
Novo Nordisk diabetes drug Victoza (liraglutide) has been approved by the US FDA for treating major cardiovascular diseases associated with type 2 diabetes.
In a significant advancement for diabetes care, Danish pharmaceutical giant Novo Nordisk has received approval from the U.S. Food and Drug Administration (FDA) to use its diabetes drug Victoza (liraglutide) for treating heart diseases associated with type 2 diabetes. This approval marks a pivotal expansion of Victoza’s usage, positioning it as a key player in […]